Position in LLY
as of Jun 30, 2026
· filed Jul 17, 2026
Position Value
$894,774
+$203,107 QoQ
Shares Held
746
-0.8% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.72%
of 13F equity value
Holder Rank
#3,242
of 4,605 holders
Holding Since
Jun 2023
13 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in LLY Over Time
Shares Held
Position Value (USD)
Derivatives in LLY
reported options exposure · as of Jun 30, 2024CallValue
$271,614
CallShares
300
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Cypress Capital, LLC holds $13,403,943 across 6 Drug Manufacturers - General names. LLY ranks #5 (6.7% of the industry book) .
All Filings in LLY
Export CSV
14 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $894,774 | 746 | Shares | Sole | 2026-07-17 | |
| 2026-03-31 | $691,667 | 752 | Shares | Sole | 2026-04-28 | |
| 2025-12-31 | $804,935 | 749 | Shares | Sole | 2026-02-06 | |
| 2025-09-30 | $604,296 | 792 | Shares | Sole | 2025-10-23 | |
| 2025-06-30 | $528,521 | 678 | Shares | Sole | 2025-08-07 | |
| 2025-03-31 | $420,388 | 509 | Shares | Sole | 2025-04-25 | |
| 2024-12-31 | $449,304 | 582 | Shares | Sole | 2025-02-03 | |
| 2024-09-30 | $505,871 | 571 | Shares | Sole | 2024-11-12 | |
| 2024-06-30 | $479,851 | 530 | Shares | Sole | 2024-10-28 | |
| 2024-06-30 | $271,614 | 300 | Call | Sole | 2024-08-22 | |
| 2024-03-31 | $411,540 | 529 | Shares | Defined | 2024-10-29 | |
| 2023-12-31 | $307,198 | 527 | Shares | Defined | 2024-12-02 | |
| 2023-09-30 | $300,255 | 559 | Shares | Defined | 2024-12-02 | |
| 2023-06-30 | $260,752 | 556 | Shares | Defined | 2024-12-02 | |
| No filing history on record for this holder in this stock. | ||||||